|| Checking for direct PDF access through Ovid
Yes. For the treatment of atrial fibrillation, patients given rivaroxaban have similar or lower total costs than patients given warfarin (including medications, laboratory costs, hospitalizations, outpatient/emergency visits, and transportation) over the short term (SOR: B, consistent cohort studies). Rivaroxaban is also likely cost effective after 16 years compared with warfarin for treatment of nonvalvular atrial fibrillation (NVAF) (SOR: B, cost-effectiveness simulation). For treatment of venous thromboembolism (VTE), there is a 98% likelihood that rivaroxaban is cost saving compared with warfarin (SOR: B, cost-effectiveness simulation).